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ABSTRACT
Introduction HIV transmission within serodifferent
heterosexual couples plays a key role in sustaining the
global HIV pandemic. In the USA, transmission within
established mixed-status couples accounts for up to half of
all new HIV infections among heterosexuals. Oral HIV pre-
exposure prophylaxis (PrEP) is a highly effective prevention
method, although underutilised among serodifferent
couples. Moreover, there is a dearth of research on US
HIV-serodifferent couples’ perspectives and use of PrEP,
alone or in combination with other prevention methods.
In this paper, we describe the study protocol for the
Magnetic Couples Study, designed to fill critical knowledge
gaps regarding HIV-serodifferent heterosexual couples’
perspectives, experiences and utilisation of PrEP.
Methods and analysis The Magnetic Couples Study is
a mixed methods prospective cohort study designed to
describe temporal patterns and identify determinants at
multiple levels (individual, couple, HCF) of PrEP outcomes
along the care continuum (PrEP awareness, linkage,
uptake, retention and medication adherence) among HIV-
serodifferent heterosexual couples residing in New York City.
The study will also examine clinical management of PrEP,
side effects and changes in sexual-related and substance
use–related behaviour. A prospective cohort of 230 mixed-
status couples already on oral PrEP was recruited, with
quarterly assessments over 18 months; in addition, a cross-
sectional sample of 150 mixed-status couples not currently
on PrEP was recruited. In-depth semistructured qualitative
interviews were conducted with a subsample of 25 couples.
Actor-partner interdependence modelling using multilevel
analysis will be employed for the analysis of longitudinal
dyadic data. Framework analysis will be used to analyse
qualitative data. A parallel convergent design will be used for
mixed methods integration.
Ethics and dissemination The study was approved by
the University of Rochester Institutional Review Board
(RSRB00052766). Study findings will be disseminated to
community members and providers and to researchers
and policy makers.

Strengths and limitations of this study
►► Prospective cohort study of pre-exposure prophylax-

is (PrEP) implementation involving HIV-serodifferent
heterosexual couples in the USA, a high-risk but understudied population.
►► Longitudinal collection of quantitative, qualitative,
biological and medical record data, including objective measures of PrEP adherence.
►► Examination of multilevel (individual, couple, healthcare facility) determinants of PrEP outcomes on the
continuum of care.
►► Sampling of study participants receiving PrEP and
antiretroviral therapy across multiple healthcare
facilities allowing for examination of site-
level
determinants.
►► Threats to internal and external validity include bias
from self-
reported measures, sampling bias and
lack of generalisability to non-urban areas.

BACKGROUND
HIV transmission within heterosexual couples
in which one partner is HIV-
negative and
the other is living with HIV—so-called HIV-
serodifferent couples—plays a key role in the
global HIV pandemic,1–5 with couple-linked
seroconversions accounting for between 30%
and 50% of new HIV infections.4 6 7 In the
USA, about one-in-four heterosexuals living
with HIV has an established primary sexual
partner who is HIV-
negative;8–19 and such
‘mixed-status’ or ‘magnetic’ couples account
for up to half of all new HIV infections among
heterosexuals nationally.20 The risk of HIV
transmission within serodifferent couples
has been observed to vary widely, from 0%
to 20% per annum, depending on the type
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and frequency of sexual behaviour and use of prevention
methods.21
Until relatively recently, condoms were the only effective method of preventing HIV transmission within serodifferent couples. However, despite awareness of their
mixed HIV status, consistent condom use among serodifferent couples ranges across studies from a low of 20%
upwards to 75%.12 16 22–24 Moreover, male condoms are only
70%–80% effective at preventing HIV transmission.25–27
In contrast, robust evidence has shown that maintaining
an undetectable viral load in the partner living with HIV
provides complete protection from sexually transmitted
HIV in serodifferent couples—affirming the dictum
Undetectable=Untransmittable (U=U).28–30 Yet, there is
limited evidence on the extent to which HIV-serodifferent
couples are able to sustain viral suppression; a few studies
indicate that only about half of partners living with HIV
in mixed-status heterosexual couples are able to maintain
long-term viral control (ie, sustained undetectable viral
load).23 31 Barriers to sustained undetectable viral load
include social determinants of health including racism,
homelessness, poverty and access to medical care, which
can inhibit one’s ability to adhere to a daily medication
regimen.32–35 Oral HIV pre-exposure prophylaxis (PrEP;
200 mg emtricitabine (FTC) in combination with 300 mg
tenofovir disoproxil fumarate (TDF) or 25 mg tenofovir
alafenamide (TAF)) has been added to the HIV prevention toolbox within the last decade. When taken daily as
an oral medication, PrEP has demonstrated high levels of
efficacy (>95%) in preventing HIV transmission among
HIV-serodifferent heterosexual couples.36 37
The US Centers for Disease Control and Prevention and
the WHO have consequently recognised HIV-serodifferent
couples as a high-priority group and have issued recommendations for PrEP and antiretroviral therapy (ART)
to prevent dyadic transmission.38–40 However, there is
a lack of data on PrEP awareness, acceptability, uptake
and adherence among HIV-
serodifferent heterosexual
couples in the USA.20 41 There is also a dearth of research
on couples’ perspectives and use of PrEP in combination
with ART and other prevention methods, and on the
factors at multiple levels (individual, couple, healthcare
facilities (HCFs)) that account for enacted prevention
strategies in these couples.42–44 In addition, there is little
evidence on how different HIV prevention strategies
might affect sexual and substance use–related behaviours
among US mixed-status couples.20
The Magnetic Couples Study is an ongoing prospective
cohort study funded by the National Institutes of Health,
National Institute of Mental Health (R56MH103047;
R01MH107371), designed to fill critical knowledge
gaps regarding HIV-serodifferent heterosexual couples’
perspectives on and experiences in the PrEP care
continuum, with the goal of providing an evidence base
to inform tailored HIV prevention interventions for this
group. The specific aims of the Magnetic Couples Study
are as follows: (1) examine trends and identify multilevel
(individual, couple, HCF) determinants of awareness,
2

acceptability, uptake and retention of oral PrEP use
among HIV-negative partners in US serodifferent heterosexual couples; (2) describe the temporal patterns and
identify multilevel determinants of daily oral PrEP and
ART adherence in both members of HIV-serodifferent
couples, including the pharmacokinetic relationship
between self-reported PrEP adherence and FTC/TDF/
TAF drug concentrations in blood; (3) describe the
temporal patterns and identify determinants of PrEP care
utilisation compliance with recommended HIV testing
and clinical management (PrEP visits, HIV testing and
ancillary tests, counselling) as well as side effects and
toxicity among PrEP users; and (4) identify predictors of
changes in sexual and substance use–related behaviours
among PrEP users and their partners living with HIV. In
the current paper, we describe the study protocol of the
Magnetic Couples Study.

METHODS AND ANALYSES
Design and samples
The Magnetic Couples Study employs a mixed methods
observational design to characterise trends in PrEP use
and identify deterrents and facilitators at multiple levels
at each stage of the PrEP care continuum among heterosexual HIV-
serodifferent couples. The study does not
include provision of clinical care to participants, but
examines PrEP utilisation and determinants of care as
they occur in real-world settings. The study population
consists of mutually disclosed HIV-serodifferent heterosexual couples in which members are age 18 years or
older; in a primary heterosexual relationship for at least
3 months and have engaged in vaginal or anal sex in the
last 30 days; are fluent in either English or Spanish; and
reside in or around the New York City area. The construct
of heterosexuality was based on dyadic identity as an
opposite-gender/opposite-sex couple and could include
both cisgender and transgender persons.
The HIV-serodifferent sample (n=580; 290 dyads) is
composed of two arms: one consisting of a prospective
cohort sample (n=460; 230 dyads), for which the HIV-
negative partner had a current prescription for PrEP at
the time of baseline enrolment; and the second consists
of a cross-sectional sample (n=300; 150 dyads), for which
the HIV-negative partner did not have a current PrEP
prescription (figure 1). Couples in the non-PrEP arm
were allowed to enrol into the PrEP cohort if they later
received a PrEP prescription. Thus, the final sample of
290 unique couples include 230 couples enrolled in the
prospective PrEP cohort (140 enrolled directly into the
PrEP arm plus 90 couples referred from the non-PrEP
arm) and 60 couples from the non-PrEP arm not referred
to the PrEP cohort. A purposive subsample (n=25 dyads)
drawn from the prospective cohort will be selected to
participate in semistructured in-depth qualitative interviews to provide contextual data to aid in the interpretation of quantitative findings.
McMahon JM, et al. BMJ Open 2021;11:e048993. doi:10.1136/bmjopen-2021-048993
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Figure 1 Couple enrolment into pre-exposure prophylaxis
(PrEP) and non-PrEP study arms.

Timeline
Prospective cohort participants are enrolled in the study
for an 18-month period, with data collection assessments
at intake and at 3-month intervals (maximum seven observations per participant). Both members of each couple
provide authorisation to access medical records spanning
the period from 18 months prior to study enrolment to
their terminal follow-up assessment (total 36 months).
Intake enrolment for the study has been completed (June
2016–December 2019) and follow-
up assessments are
expected to be completed by late 2021.
Patient and public involvement
This 5-
year PrEP implementation study, supported
by the National Institute of Mental Health (NIMH;
R01MH107371), was preceded by a National Institutes
of Health (NIH) ‘High Priority, Short-
Term Project
Award’ (R56MH103047) designed to provide interim
support for ‘highly meritorious’ … ‘creative and innovative approaches’ prior to receiving full NIH funding.
Conducted from September 2014 to February 2016,
our team used this period of support to perform formative work in preparation for the full study, including
conducting in-depth interviews with 27 HIV-serodifferent
couples and 15 PrEP providers. We also interviewed
administrators and formed partnerships with over 40
HCFs, service agencies and community-based organisations in New York City. This formative work helped inform
all aspects of the study design and data collection. The full
study protocol was pilot tested with 10 HIV-serodifferent
couples prior to enrolling research participants. Public
and stakeholder involvement continued during the main
study in close consultation and involvement with the New
York City PrEP Task Force composed of PrEP providers,
patients, advocates, researchers and other stakeholders.
Recruitment and enrolment
Recruitment efforts focused on increasing awareness of
the study among HIV-serodifferent heterosexual couples
in the New York City area by employing five primary
methods: (1) distribution of study posters and pamphlets
(figure 2); (2) passive referrals from clinics, service agencies and community-based organisations; (3) social media
campaign (Facebook, Twitter, Craigslist; project website);
(4) traditional advertisements in newspapers, magazines,
McMahon JM, et al. BMJ Open 2021;11:e048993. doi:10.1136/bmjopen-2021-048993

Figure 2 English version poster for the Magnetic Couples
Study (Image source: Getty Images #476852698).

subway signs and radio; and (5) peer-
referral with a
maximum of three referrals per enrolled couple. These
methods directed those interested in the study to contact
study staff directly by calling a toll-free phone number,
text messaging, emailing or accessing the study website
to obtain further information and undergo initial eligibility screening. Those who met the eligibility criteria
were offered assistance for informing and recruiting their
primary partner into the study using strategies developed
by Witte and colleagues.45
Once both members of the couple were deemed
eligible, an appointment was scheduled for them to visit a
centrally located research office in mid-town Manhattan
and undergo eligibility verification, informed consent
and intake assessment. Eligibility verification consisted
of re-screening, HIV testing to confirm HIV-serodifferent
status and administration of a couple verification screener
to ensure that dyads were primary sexual couples.46 47
Eligible couples in which the HIV-negative partner had
a current PrEP prescription (verified by the date on their
PrEP medication bottle) were enrolled into the prospective cohort PrEP arm of the study; whereas couples not
taking PrEP were enrolled into the cross-sectional non-
PrEP arm of the study. If couples in the non-PrEP arm
3
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Table 1 Description of study measures and data collection
Data type

Subjects/Source

Collection method (frequency)

Quantitative surveys

Prospective PrEP arm participants and
cross-sectional non-PrEP participants (each
member of the couple surveyed separately)
Prospective PrEP arm participants (HIV-
negative and HIV-positive partners)

Audio computer-assisted self-interviews (ACASI) (PrEP
arm participants: intake, quarterly; non-PrEP arm
participants: intake)
Retrospective chart review and electronic extraction
from participating clinics (past 3 years of records
obtained at terminal follow-up)

HIV antibody test

Prospective PrEP arm and cross-sectional
non-PrEP arm participants

OraQuick Rapid Antibody Test Advance HIV-1/2 test
(intake: HIV-positive partner (both arms); HIV-negative
non-PrEP arm (intake and quarterly: HIV-negative PrEP
arm))

Serum creatinine level

Prospective PrEP arm, HIV-negative partner

Dried blood spot (DBS) assay for creatinine (intake and
quarterly)

PrEP drug levels

Prospective PrEP arm, HIV-negative partner

DBS assay for quantification of TFV-DP (TDF, TAF) and
FTC-TP (intake and quarterly)

Qualitative interviews

Purposively selected PrEP arm participants
(each member of the couples interviewed
separately)
Extracted from quantitative surveys; medical
records; public sources

Semistructured face-to-face interviews, audio recorded
and transcribed (one-time during prospective period)

Medical records

Healthcare facility
characteristics

Secondary data extraction

FTC-TP, emtricitabine triphosphate; PrEP, pre-exposure prophylaxis; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; TFV-DP,
tenofovir-diphosphate.

expressed an interest in PrEP, a referral was made to a
PrEP provider at a preferred location. Couples enrolled
in the prospective PrEP cohort who broke up during the
study period were allowed to be retained in the study, but
follow-up assessments for former partners were scheduled
on different days. Survey data were collected on relationship status, break-ups and establishment of new relationships, which may have an impact on PrEP outcomes.
Allowing both members of dissolved couples to remain
in the study also reduced the risk of potential partner
conflict. Contact information was collected and entered
into a locator form for all enrolled couples. Each member
of the couple is paid US$75 for each completed office
visit assessment, in addition to a travel reimbursement of
US$5.50 for subway fares to and from the research office.
Enrolled couples are also paid US$10 for each couple
they refer into the study, with a limit of three referrals
per couple.
Measures and data collection
The Magnetic Couples Study involves the collection
of multiple types of data: quantitative surveys, medical
record chart review and extraction, biological assays
and qualitative interviews (table 1). Consistent with our
specific aims, study outcome measures include PrEP
acceptability, uptake, and retention (Aim 1), PrEP adherence (Aim 2), utilisation of PrEP clinical care and PrEP-
related side effects (Aim 3), and sexual and substance
use–related behaviour change (Aim 4).
Quantitative surveys
Structured quantitative surveys are administered to all
enrolled participants in either English or Spanish by
4

trained bilingual interviewers using a combination of
computer-assisted personal interview (CAPI) and audio
computer-
assisted self-
interview (ACASI) methods
(online supplemental file 1). Couples are interviewed
concurrently but separately in private offices. Members
of HIV-
serodifferent couples in the prospective PrEP
arm complete the survey at baseline and quarterly for 18
months, whereas couples in the non-PrEP cross-sectional
arm complete only a single intake survey. Surveys last
between 1 and 1.5 hours and are designed with skip
patterns such that each survey is tailored to the characteristics of the participant.
Quantitative survey items encompass ten major
domains: (1) Demographics (eg, age, race, ethnicity,
economic indicators, family composition); (2) General
Health (eg, physical and mental health and treatment,
history of sexually transmitted infections, reproductive
health); (3) Health Systems (eg, provider satisfaction, access
and barriers to care, healthcare utilisation); (4) Healthcare
Costs (eg, insurance coverage, assistance programmes,
out-of-pocket expenses); (5) Structural Factors (eg, stigma,
discrimination, incarceration); (6) Psychosocial Factors
(eg, social support, resilience); (7) Relationship Function
(eg, gender roles, conflict resolution, communication,
balance of power, closeness, commitment, trust, intimate
partner violence); (8) HIV (eg, ART adherence, disclosure); (9) PrEP (eg, awareness, knowledge, acceptability,
utilisation, adherence, formulation preference); (10)
HIV Exposure and Prevention (eg, perceived HIV vulnerability, condom attitudes and use, viral suppression, sexual
behaviour, substance use behaviour).
McMahon JM, et al. BMJ Open 2021;11:e048993. doi:10.1136/bmjopen-2021-048993
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Medical records
Participants enrolled in the prospective PrEP arm are
asked to voluntarily provide Health Insurance Portability
and Accountability Act (HIPAA) authorisation to release
their medical records obtained from their HCFs delivering ART (for participants living with HIV) or PrEP care
(for HIV-negative participants); authorisation forms are
completed at intake and updated at terminal follow-up
assessment and requests to release medical records are
submitted to appropriate HCFs to obtain participant
records covering the preceding 36 months. Data obtained
from medical records consist of 60 items per office visit
and are extracted under the supervision of a nurse study
coordinator trained and experienced in medical chart
review and extraction. Medical record data cover the
following domains: office visit date and purpose; health
insurance; vital signs; major diagnoses (physical, mental
and sexual health); tests and procedures performed; HIV
test results; HIV biometrics (eg, CD4; viral load); ART
adherence (provider notes from patient reports or pharmacy refill); ART regimens; PrEP history and care; other
prescription medications; kidney and liver function;
bone mineral density; vitamin/supplement use; ancillary
services; and sexual history.
HIV antibody test
The HIV-serodifferent status of all couples (PrEP and
non-PrEP arms) was confirmed at intake by HIV testing.
In addition, all HIV-negative partners are administered
an HIV test at each follow-up assessment. HIV testing
is performed using the OraQuick Rapid Antibody Test
Advance HIV-1/2 kit, with test kit controls performed
on new batches (OraSure Technologies). Standard CDC
HIV counselling is performed as part of the HIV testing
protocol.
Serum creatinine level
As an indicator of renal function, serum creatinine levels
are measured at intake and at all follow-up visits for HIV-
negative participants in the PrEP arm. Dried blood spot
(DBS) specimens are collected from participants using
the PTS Pod System (PTS Diagnostics) and shipped to
a commercial laboratory (CoreMedica, Lee’s Summit,
Missouri, USA) where assays are run and results are
reported back via a secure portal. Creatinine levels are
then converted to creatinine clearance values applying
standard algorithms.
PrEP drug levels
PrEP (Truvada and Descovy) drug blood levels in HIV-
negative participants are quantified as an objective
measure of PrEP adherence. Descovy was approved
by the US Food and Drug Administration (FDA) for
PrEP part-way through data collection and some participants had their prescriptions switched to Descovy by
their providers. DBS specimens are collected from HIV-
negative partners enrolled in the PrEP arm at intake and
quarterly follow-up assessments using the PTS Pod System.
McMahon JM, et al. BMJ Open 2021;11:e048993. doi:10.1136/bmjopen-2021-048993

Specimens are shipped to an academic laboratory at the
University of Colorado Anschutz Medical Campus for
assay, which quantifies (1) tenofovir-diphosphate (TFV-
DP) concentration (fmol/punch(es)), an estimate of the
average amount of PrEP taken over the prior 2-month
period; and (2) emtricitabine triphosphate (FTC-
TP)
concentration (pmol/punch(es)) for which a detectable
sample indicates that the participant took at least 1 dose
of PrEP in the last 48–72 hours for Truvada and up to the
last week for Descovy.48 49
Qualitative interviews
A subsample of HIV-
serodifferent couples (n=50; 25
dyads) from the prospective PrEP arm participate in
face-
to-
face in-
depth semistructured qualitative interviews lasting about 1 hour (online supplemental file 2).
Composition of the purposive sample will ensure variation on demographics, PrEP retention and adherence,
condom use, and ART adherence and viral load. Once
long-acting injectable (LAI) PrEP is approved and available, we will conduct an additional 10–15 interviews with
HIV-
negative partners who switch to LAI-
PrEP. Interviews are conducted concurrently with each member of
the couple individually in separate private offices; each
partner receives US$50 compensation. Interviews cover
relationship dynamics, dyadic strategies for HIV prevention, sexual and substance use history, healthcare utilisation, including HIV or PrEP care, and experiences with
providers and HCFs. The audio-recorded interviews are
transcribed verbatim.
HCF characteristics
Characteristics of HCFs at which participants receive
their PrEP or ART care will be extracted from multiple
secondary data sources, including participant quantitative surveys, medical record data and public sources.
Characteristics include type (eg, primary care; sexual
health clinic), location (eg, access to public transportation), size (patient pool; number of providers), patient
resources (eg, onsite pharmacy; social services); and PrEP
and ART programmes (eg, support groups; patient navigation; financial assistance).
Data analysis
Quantitative analysis
Descriptive statistics will be used to characterise the
sample on demographics and key variables. Generalised
estimating equation (GEE) analysis will be performed
on baseline data pooled from the PrEP and non-PrEP
arms to identify predictors of PrEP acceptability and
uptake. The actor-
partner interdependence modelling
(APIM) framework using multilevel modelling (MLM)
will be employed for the analysis of longitudinal dyadic
data in order to accommodate the nested data structure
(repeated observations nested within individuals nested
within dyads) and examine mutual partner influence
over time in distinguishable dyads.50 51 This will permit
estimation of PrEP user growth trajectories on outcomes
5
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while directly assessing the impact of structural, dyadic
and partner factors (time-
variant and invariant) on
outcomes.52 53 Multilevel models will also be specified
to examine the interplay among PrEP adherence, ART
adherence/viral suppression and condom use over time.
MLM accounts for missing data (under assumptions of
missing completely at random or missing at random) by
full information maximum likelihood estimation.54 Multilevel survival analysis will be used to model time to first
event (eg, undetectable TFV-DP level), repeat events (eg,
HIV testing) and termination of states (discontinuation
of PrEP).55 56 SAS software (V.9.4; SAS Institute, Cary,
North Carolina, USA) will be used to perform descriptive, GEE and APIM-MLM analyses; MPlus (V.8.4; Muthen
& Muthen, Los Angeles, California, USA) will be used to
perform survival analysis.
Power analysis
To determine appropriate sample sizes, power calculations were performed using NCSS-
PASS software
(V.21.0.2) with alpha=0.05 and power=0.80 for two-sided
hypotheses. Based on previous observations, adjustment
for within-
dyad correlation was set to r=0.30; and for
longitudinal analysis, repeated measures correlation was
set to r=0.50; we further assumed 15% attrition at terminal
follow-
up. For GEE analysis modelling PrEP uptake
(binary outcome), a baseline sample of n=290 dyads
(PrEP and non-PrEP arm observations) can detect an
OR=1.35 or higher. For a three-level MLM of continuous
outcomes (eg, PrEP medication adherence) and time to
event (eg, time to PrEP discontinuation), a sample size of
n=460 (230 dyads) can detect an effect size of Beta=0.30
(R2=0.09).
Qualitative analysis
Transcribed audio-
recorded interviews will be loaded
into Dedoose (www.dedoose.com) software for analysis.
Following Lewis et al,57 a five-
step framework analysis
approach will be used to analyse and contextualise the
qualitative data.58 These steps include the following:
(1) Familiarisation: transcripts will be read by the qualitative analysis team and descriptive summaries of each
interview will be compiled, from which potential themes
will be described; (2) Thematic framework: an initial
set of deductive codes will be drawn from our conceptual framework and interview guides and combined with
inductive categories drawn from emergent themes identified during familiarisation, producing a nascent code/
subcode list; (3) Indexing: applying the code list, transcripts will be systematically coded with linked excerpts
by multiple team members; redundant coding, comparison and iterative code modification with quality checks
(eg, inter-rater reliability) will be used to produce a final
consensus code list; (4) Charting: at the thematic level,
a hierarchy of themes (and cross-linked codes) will be
organised by primary outcomes, socioecological level,
6

and content; (5) Mapping and interpretation: charted
themes will be summarised.
Mixed methods integration
For qualitative and quantitative data integration, we will
follow the NIH ‘Best Practices for Mixed Methods’ guidelines established by Creswell and colleagues.59 These
guidelines provide a framework and taxonomy for the
design, integrated analysis and interpretation of qualitative and quantitative data in mixed methods research.
Within this framework, we will employ a parallel convergent design, in which qualitative and quantitative data are
collected concurrently, with integration at the completion of data collection. Mixed methods data integration
will involve connecting, embedding and merging. Qualitative data will be collected from a subsample of the quantitative cohort (connecting) and will be embedded within
the larger quantitative study. Data merging will proceed
through separate parallel analyses followed by matching
on common themes using mixed data matrices structured
by level and topic area to provide comparative depth and
expansion of understanding.60 Triangulation will employ
a meta-inference framework, in which the coherence of
data integration is interpreted as either confirmation,
expansion or discordance. Confirmation occurs when
both qualitative and quantitative analyses yield corroborating results; expansion is marked by the two sources of
data illuminating different or complementary aspects of
the phenomenon; and discordance occurs when qualitative and quantitative findings are inconsistent.61 Quantitative analysis will test hypotheses regarding the association
of multilevel determinants on PrEP utilisation outcomes,
with integrated qualitative data used to confirm, expand
or contrast our understanding of how life history, contextual influences and participant perspectives shape these
associations.

ETHICS AND DISSEMINATION
The protocol and procedures for the Magnetic Couples
Study have been reviewed and approved by the institutional review board of the University of Rochester
(RSRB00052766). The inadvertent loss of confidential
and personal information is of primary concern for this
study as it could pose potential risks to participants, such
as legal consequences or social repercussions. To prevent
this from occurring, study staff will maintain strict confidentiality and HIPAA requirements. ACASI methods in
which participants directly enter responses to sensitive
items into a computer programme help maintain confidentiality. In addition, all participant data are stored in
deidentified form, with the exception of a locator form
used to schedule follow-up visits, which is stored on a
secure server with restricted access. A certificate of confidentiality was issued by the NIH to further protect sensitive information and subject confidentiality.
A second, related, ethical concern pertains to potential
partner conflict or violence stemming from couples’ joint
McMahon JM, et al. BMJ Open 2021;11:e048993. doi:10.1136/bmjopen-2021-048993
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participation in the study. Methods developed by our team
to successfully mitigate this concern include (1) being
transparent regarding the content and format of the study
protocols; (2) allowing each partner to self-select out of
the study if they are concerned about their safety; (3)
physically separating members of a couple for screening,
enrolment and data collection, and instructing them not
to discuss any aspects of the study with each other; and
(4) providing research staff with training on partner notification programmes for newly HIV-diagnosed partners,
and for dealing with and providing referrals for cases
involving intimate partner violence.62
Future dissemination of study findings will target four
primary audiences: community members, providers,
researchers and policy makers. Study findings will be
shared with community members and providers through
the dissemination of infographics through social media
and a website as well as by holding forums and presentations in appropriate venues. Researchers and policy
makers will be informed of study results primarily
through scientific and policy conference presentations
and journal articles. Emphasis will be placed on interpretation of findings towards implications for practice and
actionable steps.
DISCUSSION
Although the efﬁcacy of daily oral PrEP for HIV prevention
in heterosexual serodifferent couples is well established,
implementation research examining determinants of
PrEP uptake, retention, adherence and clinical management among US mixed-
status heterosexual couples is
lacking.20 Despite the many ongoing and completed
PrEP demonstration and implementation projects,63 to
our knowledge, the Magnetic Couples Study is the only
prospective cohort study to examine PrEP implementation among HIV-
serodifferent heterosexual couples in
the USA.
In this paper, we describe the study protocol of the
Magnetic Couples Study, which was developed through
a collaboration of researchers at the University of Rochester, the New York City Department of Health and
Mental Hygiene, New York University, Columbia University, Massachusetts General Hospital/Harvard University,
and the University of Colorado in partnership with over
40 HCFs, service agencies and community-based organisations in New York City.
Strengths of the study include (1) implementation of a
mixed methods multilevel approach involving the collection of quantitative and qualitative data; (2) collection of
data on the characteristics of HCFs where participants
receive their ART or PrEP care, allowing for analysis of
associations with HCF characteristics; (3) extraction of
study participants’ medical record data from clinical sites
to assess medical history, ART and PrEP care, and healthcare utilisation; (4) assays of DBS samples collected from
HIV-negative partners at each assessment visit to objectively measure PrEP adherence; (5) HIV-testing of both
McMahon JM, et al. BMJ Open 2021;11:e048993. doi:10.1136/bmjopen-2021-048993

partners at intake to confirm HIV-serodifferent status,
and continued HIV testing of the negative partner to
document seroconversions; (6) collection of data from
both members of HIV-serodifferent couples, which allows
for more accurate modelling of measurement error,
dyadic function and mutual influence; (7) 18-
month
follow-up assessments on quantitative surveys and biological data and 36-month medical record review allowing
for analysis of longer-term trends in ART and PrEP utilisation and their determinants; (8) a comparative sample of
HIV-serodifferent couples not on PrEP including a subsample of those who subsequently initiate PrEP and enrol
in the prospective cohort, thus allowing for modelling of
PrEP uptake as well as retention in care and adherence;
and (9) a sampling plan designed to reach participants
through multiple forms of media as well as via agency and
peer referrals, thus not limited to a few clinical sites.
A number of methodological limitations are also
inherent in the study. There is a potential for sampling
bias favouring couples who are capable of visiting our
research office in mid-town Manhattan during regular
working hours; although we attempt to accommodate
some couples by scheduling assessments after hours or
on weekends, the majority of assessments are conducted
during regular work hours. The study is also limited to
couples residing in the New York City area and findings may not generalise to less urbanised areas or other
regions of the USA. However, New York City contains the
highest prevalence of persons living with HIV nationally,
including heterosexuals in serodifferent relationships.
Our study was open to transgender men and women,
as long as they reported being in an opposite-gender
serodifferent relationship, but the small subsample of
transgender persons enrolled in the study might lack
adequate power to perform subgroup analysis. In addition, study results may not fully generalise to same-sex
couples as PrEP provision among such couples may be
affected by a unique set of determinants and relationship
dynamics.20 64–66 Much of the quantitative data is based
on self-report, which can be subject to various forms of
bias, including social desirability and recall bias.67 We
attempted to mitigate these sources of bias by employing
ACASI methods for sensitive items in the survey, minimising the recall period, collecting identical data from
both members of the couple to better model measurement error, and collecting key variables using biological
assays and medical chart review.
Knowledge generated from the Magnetic Couples
Study will help inform the development of couple-based
models of care for dual HIV treatment and prevention
involving HIV-serodifferent heterosexual couples. Such
couple-
based interventions, while not uncommon in
African countries, remain relatively untapped in the
USA.68 Successful provision of PrEP in this group requires
an understanding of factors operating concurrently at
multiple levels (individual, couple, HCF) that facilitate or impede optimal implementation. The Magnetic
Couples Study will identify multilevel time-variant and
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time-
invariant determinants of PrEP implementation
outcomes among a cohort of HIV-serodifferent heterosexual couples over an 18-month assessment period. Findings will inform optimal methods for healthcare providers
across different settings to provide effective models of
PrEP and ART care delivery for HIV-serodifferent USA
couples, including issues related to ethics and conﬁdentiality surrounding couple-based care.
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